MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

86.68 -2.28

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

85.91

Максимум

89.59

Ключови измерители
By Trading Economics
Приходи	-6.2M -49M
Продажби	-9.1M 33M
Марж на печалбата	-151.352
Служители	283
EBITDA	-9.5M -47M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+7.9% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	73M 4.1B
Предишно отваряне	88.96
Предишно затваряне	86.68

Настроения в новините

By Acuity

34%

66%

108 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.07.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FCC Approves U.S. Cellular Sale to T-Mobile

11.07.2025 г., 17:28 ч. UTC

Значими двигатели на пазара

SharpLink Gaming Gains on Ethereum Purchase

11.07.2025 г., 16:57 ч. UTC

Печалби

BASF Cuts Outlook on Global Economy Uncertainty

11.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11.07.2025 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11.07.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11.07.2025 г., 18:18 ч. UTC

Пазарно говорене

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11.07.2025 г., 17:35 ч. UTC

Пазарно говорене

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11.07.2025 г., 16:53 ч. UTC

Пазарно говорене

Crude Futures Add to Early Gains -- Market Talk

11.07.2025 г., 16:42 ч. UTC

Печалби

BASF Cuts Outlook on Global Economic Uncertainty

11.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11.07.2025 г., 16:05 ч. UTC

Печалби

BASF Will Publish Half-Year Results on July 30

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11.07.2025 г., 16:03 ч. UTC

Печалби

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11.07.2025 г., 16:02 ч. UTC

Печалби

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11.07.2025 г., 16:01 ч. UTC

Печалби

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11.07.2025 г., 16:00 ч. UTC

Печалби

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11.07.2025 г., 15:59 ч. UTC

Печалби

BASF Cuts 2025 Earnings View

11.07.2025 г., 15:58 ч. UTC

Печалби

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11.07.2025 г., 15:57 ч. UTC

Печалби

BASF 2Q EBIT Before Special Items EUR810M

11.07.2025 г., 15:54 ч. UTC

Печалби

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11.07.2025 г., 15:54 ч. UTC

Печалби

BASF 2Q Sales Fell 2.1% on Year

11.07.2025 г., 15:53 ч. UTC

Печалби

BASF 2Q Sales EUR15.77B

11.07.2025 г., 15:52 ч. UTC

Печалби

BASF: This Was in Line With Consensus Estimates

11.07.2025 г., 15:52 ч. UTC

Печалби

BASF 2Q Ebitda Before Special Items EUR1.77B

11.07.2025 г., 15:49 ч. UTC

Печалби

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11.07.2025 г., 15:41 ч. UTC

Пазарно говорене

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

7.9% нагоре

12-месечна прогноза

Среден 96.07 USD 7.9%

Висок 129 USD

Нисък 69 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

108 / 376 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.